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Objectives: The Lack of Adherence to Immunosuppressive Treatment (LAIT) 
has been associated with Chronic Humoral Rejection (CHR) and decreased graft 
survival which can increase Health Resource Utilisation (HRU). Prevalence of 
LAIT has been reported to range between 7.4% and 41.8% of Spanish Kidney 
Transplant (KT) patients and published studies suggest LAIT may cause up to 
20-50% of CHR episodes in Spain. The objective of this study was to estimate the 
resource utilization associated with LAIT in KT patients in Spain. MethOds: 
A systematic literature review was conducted using Medline, PsycINFO and 
BVS to identify Spanish studies published between 2009 and 2013 focusing on 
KT and LAIT. Following the review a questionnaire was developed to explore 
HRU associated with LAIT. Six national experts in KT from Spain completed 
the survey and the data was analyzed using Computer Assisted Qualitative 
Data Analysis (CAQDAS). HRU was estimated independently for suspected 
LAIT, suspected CHR, confirmed CHR and graft loss. Results: Suspected LAIT 
and CHR were associated with additional HRU quantified by additional neph-
rologist visits, heightened immunosuppressive blood-level monitoring, and 
2 measurements of anti-HLA antibodies (Luminex), 1 ultrasound scan and 1 
kidney biopsy. Confirmed CHR was associated with additional HRU such as 
increases in the number of follow-up visits from 1 visit every 4-6 months to 1 
visit every 1-2 months, associated monitoring and testing (bloods, ultrasonog-
raphy, donor-specific antibodies, proteinuria). A proportion of these patients 
are treated with intravenous immunoglobulin, rituximab and plasmapheresis, 
and kidney biopsy to check whether CHR is resolved. Finally, most CHR epi-
sodes, up to 60%, cause graft loss with increased HRU associated with intensive 
patients’ follow-up to prepare the return to dialysis and renal replacement ther-
apy. cOnclusiOns: The lack of adherence to immunosuppressive treatment 
may lead to CHR and graft loss with an associated increase of healthcare resource 
utilization.
PUK19
ComParative evalUation of PCr-rflP of SSU rna and CowP Gene for 
deteCtion of CryPtoSPoridiUm SPeCieS in PatientS with PoSt renal 
tranSPlant diarrhoea
Ranjan P, Ghoshal U, Sharma RK, Ghoshal UC
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Objectives: To study the utility of SSU rRNA and COWP gene PCR-RFLP for the 
detection of C. parvum, C. hominis, C. meleagridis, and C. andersoni. MethOds: 
845 stool samples from 323 patients in renal transplant (RT) recipients and 50 
healthy controls between January 2006 and August 2011 were examined for 
Cryptosporidium by Modified acid-fast (Kinyoun’s) staining technique. DNA was 
extracted and was subjected to PCR-RFLP for species detection in cases positive for 
Cryptosporidium by microscopy. Results: Cryptosporidium was detected more 
commonly among the RT recipients than healthy controls (23/323, vs. 0/50, respec-
tively; p= 0.005). All the Cryptosporidium positive cases (23/23) were detected using 
the PCR-RFLP of SSU rRNA gene, 15/23 were C. hominis and 8/23 were C. parvum. 
Only 17/23 cases were detected by COWP genes of which 9/17 were C. hominis 
and 8/17 were C. parvum. By comparing the SSU & COWP gene PCR-RFLP with 
microscopy as the gold standard, SSU gene PCR-RFLP proved to be more sensitive 
& specific (100%) than COWP (sensitivity & specificity of COWP PCR-RFLP was 
73.9% and 100% respectively). C. meleagridis and C. andersoni were not detected 
in any case. cOnclusiOns: Cryptosporidiosis is a common cause of diarrhea 
in RT recipients. The most common species was Cryptosporidium hominis. SSU 
rRNA PCR-RFLP is more suitable for identification of Cryptosporidium species 
than COWP.
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Objectives: To prioritize comparative effectiveness research (CER) questions to 
improve home dialysis practice using a multicriteria decision analysis (MCDA) 
framework. MethOds: Candidate CER questions (n= 13) were generated and 
refined in PICO format by an international network of nephrologists (n= 28) 
using a nominal group process. The EVIDEM framework was adapted to include 
11 criteria to assess the value of these research questions to improve prac-
tice from a holistic standpoint, including the impact, context and outcomes of 
the CER question, feasibility of study, economics and implementation of study 
findings. Quality of evidence to be generated was also included as a criterion, 
with consideration of 13 subcriteria outlining the risk of bias and precision. 
First, participants were asked to weight each criterion independently of the 
research questions. Second, for each research question, participants assigned a 
score for each criterion. Average overall values of CER questions were obtained 
by combining weights and scores using a linear model. Results: Participants 
assigned highest importance to the following criteria: Impact on patient sur-
vival and other major clinical outcomes, Unmet needs, and Feasibility of the 
CER question. Value of CER questions varied between 48% and 73% of maximum 
value on the MCDA scale. Highest value estimates (> 70%) were obtained for 
research questions exploring the association between vascular access or dialysis 
selection process and mortality/morbidity. Ranking had excellent face validity 
for all criteria. Results of this ranking process were used to prioritize research 
planning for the international network of nephrologists. cOnclusiOns: 
Holistic MCDA provides a useful tool for comparative effectiveness 
research to ensure prioritization of CER questions with highest benefits 
for improving clinical practice, as illustrated by this application for home 
dialysis.
The medication adherence rate scores of the patients at academic hospital 
(4.35 ± 1.31), corporate hospital (4.38 ± 1.10) and government hospital (4.16 ± 
1.28). cOnclusiOns: The overall mean medication adherence rate score of the 
patients is 4.34 ± 1.23 and there is no significant difference in mean scores among 
hemodialysis centres (p 0.722). The health care professionals need to educate the 
patients about their disease state and importance of adherence to prescribed 
medications.
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Objectives: This study aimed to build a conceptual framework in patients with IC/
PBS which is a chronic debilitating condition characterized by pelvic pain, urinary 
urgency, and urinary frequency. It affects around 0.7-1 million people in the US and 
mostly middle aged women. Diagnostic criteria developed for research are not effi-
cient and missing 60% of all cases. Uncertainty surrounds definition, etiology, diag-
nosis, natural history, true prevalence, and most effective treatment(s). MethOds: 
Literature review results were used to design semi-structured telephone inter-
views to elicit concepts of importance for IC/PBS patients on functioning and life. 
Interviews were held with clinical experts and UK patients until saturation of 
concepts. Transcripts were analyzed thematically. Results: Two clinical experts 
and 30 female patients were interviewed. IC/PBS was defined as a chronic pain 
syndrome that may begin as a pathologic process in the bladder in most (but not 
all) patients. Pain and frequency were reported as the most bothersome symptoms. 
Relationships, activities, energy levels, and psychological impact were reported to 
be the key areas of impact. ‘Not being able to do what I used to’ , ‘worry about toilet 
access’ , ‘impact on work life’ , and ‘impact on family / home life’ were mentioned as 
having the greatest impact. A broad range of treatments was reported with a broad 
range of treatment side effects. The experts’ results contributed the following: pain 
drives frequency and younger people report a heavier burden. cOnclusiOns: The 
conceptual framework of this study contributes to the understanding of IC/PBS. IC/
PBS has a profound and debilitating effect on all aspects of patients’ lives, from 
preventing them to work over participating in family life and traveling to being 
house-bound with greatly impacted change in roles and self-perceptions, lead-
ing to feelings of being ‘not-normal’ causing anxiety, depression and even suicidal 
tendencies.
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Objectives: The medical management of men with Lower Urinary Tract 
Symptoms often involves agents targeting bladder outlet obstruction (BOO) such 
as α -blockers or 5-α reductase inhibitors (5ARI). However, overactive bladder 
(OAB) symptoms may coexist with BOO. This study aims to describe the base-
line characteristics of men who utilize OAB [mirabegron and antimuscarinics 
(AM)] therapy and sequential and combination use of various urologic medica-
tion classes. MethOds: Data from a US commercial database were analyzed for 
men starting OAB therapy between 10/01/12 and 12/31/13. Men were grouped by 
initiation of mirabegron or AM. A 12-month retrospective analysis was conducted 
with patients defined as naïve or experienced to AM therapy 12-month period 
prior to index. Baseline demographics and comorbid conditions were compared. 
Concomitant BOO medications, in use at baseline, initiated, or discontinued during 
the 90 days pre/post index date of mirabegron or AM, were analyzed. Results: 
More men on mirabegron saw a urologist (75% vs 35%), more likely to have BOO 
diagnosed (66% vs 49%) and use in free combination with α -blockers (26% vs 17%) 
and 5ARI (7% vs 4%) therapy versus AM. Baseline characteristics showed mira-
begron patients were older (64 vs 59) and had a higher Elixhauser comorbidity 
index (4.7 vs 4.0) compared with AM patients. Baseline health resource utiliza-
tion (HRU) was higher among the mirabegron cohort for urodynamic (58% vs 
29%), cystoscopy (25% vs 19%), polypharmacy (10.4 vs. 8.2) and overall outpatient 
visits (11.4 vs 8.5). More mirabegron patients had prior prostate (7.6% vs 5.8%) 
and OAB (3.9% vs 0.7%) surgical therapy 12-months prior to index compared to 
AM patients. cOnclusiOns: Male patients receiving mirabegron showed dis-
tinct baseline characteristics. Patients managed by urologists were often more 
complicated with greater baseline HRU. Additional studies to model the impact 
of patient characteristics on outcomes in those prescribed mirabegron and AMs 
may be helpful.
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